Filter Results
Filter Results
Advanced Synthesis (14) Cell & Gene (5) Integrated Biologics (44) Small Molecules (14) Specialized Modalities (5)
Allogeneic (2) Autologous (2) Bioconjugates/ADC (3) Exosomes (1) Expression Technologies (16) iPSCs (1) Mammalian (22) Microbial (3) mRNA (3) Parenteral Drug Product (4) Viral Vectors (4)
Antibody Drug Conjugates (1) Bioavailability Enhancement (3) Bispecific Antibody (12) Difficult to Express Proteins (12) Drug Substance (API/HPAPI) (8) Enhanced ADCC (4) Fabs, Fusion, Scaffold and other Recombinant Proteins (5) Inhalation (2) Injectables (2) Lipid Nanoparticle Encapsulation (1) Monoclonal Antibody (13) Oral Drug Products (5) Particle Engineering (2) Solid Form Services (2)
Analytical Development (3) Antibody Humanization & Deimmunization (1) API Services (1) Bispecific DNA-to-IND (1) Cell Line Development (18) Clinical Supply Services (11) Commercial Supply Services (4) Early De-risking & Optimization (6) First-in-Human Services (5) Formulation Development and Optimization (4) Ibex® Dedicate (1) Immunogenicity Assessment (1) IND-to-BLA (3) Manufacturing: cGMP (3) Manufacturing: GMP Drug Substance (3) Manufacturing: Non-GMP Manufacture (1) Parenteral Drug Product Development (1) PBPK Modeling (1) Process Development and Optimization (5) Regulatory Services (3) Solid Form Services (1) Strain Development (2) Tech Transfer (2) Viral Vector Expression Technologies (3)
4D-Nucleofector LV (1) bYlok™ Bispecific Antibodies Technology (1) Cocoon® Platform (1) GS Discovery® (3) GS Effex® (4) GS Gene Expression System® (10) GS piggyBac® Transposon System (9) GS Xceed® Gene Expression System (10) GSquad® Vectors (4) Hot Melt Extrusion (1) LNP (1) Mammalian Expression Technologies (18) Microbial Expression Technologies (3) Micro-dosing/Powder-in-capsule (1) Particle Size Reduction (1) Spray Dried Dispersions (2) Technology Selection (2) Viral Vector Expression Technologies (3) XS Technologies® (2)
Article (63)
ArticleX
Reset Filters
   Loading...
Showing 1‐28 of 63
Article
10 min read
Streamlining early phase drug development with continuous flow technologies
As small molecule complexity increases, early-stage development faces new challenges that demand innovative solutions. At Lonza Advanced Synthesis the continuous flow process is integrated into early phase development, allowing for optimization of chemica...
Article
5 min read
Accelerating Drug Development with Precision Powder Micro-Dosing
Drive innovation in early-stage drug development with precision powder micro-dosing.
Article
Women In Science Spotlight
Women In Science Spotlight featuring Inbar Friedrich Ben-Nun, Director of R&D, Lonza Cell & Gene Therapies
Article
6 min read
How Emerging Biotechs can Benefit by Partnering with a CDMO for Early Stage Development
The partnership between CDMOs and emerging biotech companies in early-stage development can be mutually beneficial. In this interview by PHARMAnetwork magazine, Dr. Raymond Donninger, Senior Director, Commercial Development, Early Development Services, an...
Article
6 min read
Considerations for Successful Tech Transfer of a Biologics Upstream Process
In this European Pharmaceutical Review article, bioprocess experts from Lonza discuss how molecular format and the product lifecycle phase impact the process, risks and outcomes of upstream technology transfer of biologics. This insightful article delves ...
Article
7 min read
An interview with Lisa Prendergast for Next Generation Gene Therapy Vectors Conference
Dr. Lisa Prendergast leads innovation for Lonza's Licensing Business Unit, supporting the growth of expression system platforms which are available through Lonza in Your Lab® programs. Her role is to provide expertise in Molecular Technologies, including ...
Article
15 min read
Powering the Development of Tomorrow’s Bispecific Antibodies
bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, and it can be difficult to remove such unwanted mispaired species...
Article
10 min read
Creating Next-Generation CHO Expression Platforms Through Application of Omics Technologies
Chinese hamster ovary (CHO)-based biomanufacturing platforms have transformed the industrial production of biologics such as monoclonal antibodies (mAbs) over the last few decades, and despite advances in alternative expression systems (E. coli, yeast, et...
Article
7 min read
Accelerating the Path to Clinical Filing Applications with Rapid Toxicology Material Delivery
The application for investigational new drug (IND) and Clinical Trial Application (CTA) is a key step in initiating clinical trials/first-in-human (FIH) trials for a drug candidate. Furthermore, its approval can help companies secure additional funding an...
Article
8 min read
Rapid Delivery of Toxicological Material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the provision of toxicology data to support INDs for new therapeutics and hence delivery of FIH studies, as Alejandro Fernandez Martell and James Berrie expla...
Article
10 min read
The Crucial Role of GS-CHO Innovation in Biopharmaceutical Progress
With a long standing track record of success, GS-CHO based expression systems have become the most widely used platform for developing and manufacturing recombinant therapeutic proteins today. But the evolving demands of the biologics industry including p...
Article
6 min read
mRNA Research Services to Accelerate Your Project
Article
8 min read
Understanding Glycosylation in Antibodies
Proteins often undergo a variety of post-translational modifications (PTMs) after their initial synthesis, including phosphorylation, methylation, acetylation, and glycosylation, among others. These modifications are essential for regulating a protein’s f...
Article
10 min read
Meet Your Lentiviral Vector Development and Supply Requirements with Xcite® Lenti, an Optimized Suspension-Based Platform Technology
Demand for lentiviral vectors (LVVs) as delivery vehicles for gene therapies is rising significantly, creating a need for robust, highly productive and scalable manufacturing processes. Lonza’s ready-to-use, suspension-based Xcite® Lenti Platform Technolo...
Article
10 min read
Making More Effective Antibody-Based Immunotherapies with the GS Effex® Cell Line
Antibody-based immunotherapies can mediate cancer cell death via multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). The level of ADCC activity has been shown to have a direct impact on their potency. One of the most effective ...
Article
A Small Biotech Recognizes the Importance in How You Think of Manufacturing in Selecting a CDMO
Manufacturing is crucial to the success of any drug development project but is too often overlooked. Dr. Andrea Cubitt, VP of External Scientific Alliances and Intellectual Property at aTyr Pharma, explains how her company has benefitted from the extensiv...
Article
Lonza Shows Flexibility with Ibex® Design Platform to Accommodate tRNA Synthetase-Derived mAbs
aTyr Pharma is a clinical stage biotech focused on translating findings from a proprietary tRNA synthetase platform to develop first-in-class therapeutics to treat fibrosis and inflammation, and monoclonal antibodies targeting solid tumor cancers and auto...
Article
3 min read
Tackling complexity: from molecule to formulation
Whatever proves the best option, the talented Lonza team has the skills to identify it, and then create a successful formulation for dosing to patients.
Article
3 min read
Simplify the Encapsulation Process of Nucleic Acid Payloads with FDmiX Technology
Enable a reliable, swift scale-up to cGMP manufacturing for mRNA encapsulation with the high-end FdmiX technology. Discover how to master challenges, streamline production and allow for faster, more predictable development of nucleic acid delivery systems...
Article
10 min read
Q&A: How to Maximise Cell Line Productivity and Efficiency
In this interview, Dr. Tabitha Bullock, a principal group leader at Lonza, tells us about some of the key considerations in cell line development and how advances in technology are improving the efficiency and productivity of cell lines. Tabitha also s...
Article
6 min read
Adaptive Bioprocessing: Utilising Inline Raman Spectroscopy for Automated Control
Substantial progress has been made over the last decade in developing Raman concentration models which generalize well across cell lines and products. This progress has allowed the technology to be practically used to continuously monitor and control key ...
Article
10 min read
Considerations for Successful Tech Transfer of a Biologic Purification Process
In this article, Lonza’s Andrew Brown, Samit Patel and Mark Whickman discuss the downstream aspects of process transfer from primary recovery of a biologic and the final filtration of the bulk drug substance.
Article
5 min read
The Power of Artificial Intelligence and Route Scouting to Navigate API Complexity
As active pharmaceutical ingredients (APIs) continue to grow more complex, process chemists must reconcile more elaborate synthetic pathways with a continued push to reach the clinic rapidly. To achieve efficient API manufacturing, drug sponsors are looki...
Article
3 min read
Transparent Communication Supports Tech Transfers of Cis-targeted Immunotherapies
Asher Biotherapeutics embarked on a search for a contract development and manufacturing organization (CDMO) that could handle Phase 2 and 3 production and commercial supply of its novel cis-targeted immunotherapies. It’s two lead candidates were in the in...
Article
3 min read
Cis-targeted Immunotherapies Need Large CDMO Expertise but also Flexibility
Asher Biotherapeutics is developing a pipeline of cis-targeted immunotherapies that selectively activate only the immune cell types that drive the desired therapeutic response. The company was seeking a contract development and manufacturing organization ...
Article
5 min read
Identify Your Lead Solid Form Early to Reduce Timelines and Downstream Costs
Devoting early-phase resources to finding the lead solid form of an active pharmaceutical ingredient (API) can save you time and resources down the road. In this Q&A, Abhijeet S. Sinha, Manager of Solid Form Services (SFS), provides a breakdown of differe...
Article
15 min read
Addressing Challenges with Clinical In-Use Testing of Biotherapeutics
The goal of in-use testing of biotherapeutics is to ensure acceptable product quality during dose preparation and administration into patients. This testing comprises of stability and compatibility studies of the materials and diluents used in the prepara...
Article
20 min read
Strategies to Optimize Expression Challenges of Multi-chain and Bispecific Antibodies
Many of today's expression platforms for recombinant protein manufacturing have been optimised for the expression of monoclonal antibodies (mAbs), often with the platform fundamentals originating from the 1990's. However, as new modalities increase in pre...